Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Alzheimer's Disease
Interventions
DRUG

MEM 1003

30 mg twice a day

DRUG

MEM 1003

90 mg MEM 1003 twice a day

DRUG

Placebo for MEM 1003

Placebo twice a day

Trial Locations (57)

10312

Staten Island

12208

Albany

18915

Colmar

19063

Media

19149

Philadelphia

20007

Washington D.C.

21286

Towson

23507

Norfolk

28655

Morganton

29303

Spartanburg

30030

Decatur

30342

Atlanta

32626

Chiefland

33009

Hallandale

33016

Hialeah

33064

Deerfield Beach

33065

Coral Springs

33137

Miami

33143

Miami

33173

Miami

33317

Plantation

33351

Sunrise

33409

West Palm Beach

33445

Delray Beach

33609

Tampa

33647

Tampa

33701

St. Petersburg

33952

Port Charlotte

34243

Sarasota

34613

Brooksville

35476

Northport

37601

Johnson City

60610

Chicago

63141

Saint Loius

70114

New Orleans

71104

Shreveport

76021

Bedford

78163

Bulverde

78217

San Antonio

84047

Midvale

85013

Phoenix

85201

Mesa

85351

Sun City

90505

Torrence

92243

El Centro

92506

Riverside

94109

San Francisco

97210

Portland

99204

Spokane

06518

Hamden

02721

Fall River

08009

Berlin

07740

Long Branch

08560

Princeton

07450

Ridgewood

08755

Toms River

05201

Bennington

Sponsors
All Listed Sponsors
lead

Memory Pharmaceuticals

INDUSTRY